Now Available: Syfovre for the Treatment of Geographic Atrophy
February 17, 2023 Apellis Pharmaceuticals, Inc. (Waltham, MA) today announced that the U.S. FDA has approved SYFOVRE™ (pegcetacoplan...
Now Available: Syfovre for the Treatment of Geographic Atrophy
FDA Approves Vabysmo to Treat Two Leading Causes of Vision Loss
Port Delivery Phase 2 LADDER AMD Study Results
7-year results from MUST
5-Year Data from CATT
2-Year Data from Protocol S
Aflibercept (Eylea) Approved to Treat Diabetic Retinopathy in Patients with DME
FDA Grants Breakthrough Therapy Designation for Lucentis in Diabetic Retinopathy
First Nonstudy Argus II Retinal Prosthesis Implanted
RPE65 Gene Therapy Shown Effective in Leber Congenital Amaurosis